Clinical role of GM-CSF in neutrophil recovery in relation to health care parameters.
Recombinant growth factors, particularly granulocyte-macrophage colony-stimulating factor (GM-CSF), have been only available for a few years. Since their introduction they have affected the management of drug-induced neutropenia, the use of dose intensive chemotherapy regimens and in the setting of autologous stem cell transplantation. This review addresses the clinical role of GM-CSF, using the data available, in neutrophil recovery in relation to various health care parameters.
Hofstra
L S
LS
Department of Oncology, University Hospital, Groningen, The Netherlands.
de Vries
E G
EG
Uyl-de Groot
C A
CA
Vellenga
E
E
D064420:Drug-Related Side Effects and Adverse Reactions; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000502:physiology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced / Q000503:physiopathology / Q000628:therapy; D009504:Neutrophils / Q000502:physiology*; D019172:Transplantation Conditioning
D016178:Granulocyte-Macrophage Colony-Stimulating Factor